In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that ...

Treatment options for patients with moderately to severely active Crohn's disease have expanded in the past decade, with ...

In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found ...

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis Published. Oct 10, 2024 8:00am EDT.

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

Johnson & Johnson (NYSE: JNJ) today announced results from the Phase 3 GRAVITI study of TREMFYA® (guselkumab), the first and only IL-23 inhibitor, demonstrating robust results in subcutaneous (SC ...

TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission.

Notably, those that had received guselkumab 200 mg IV in the induction portion then went to receive guselkumab 200 mg subcutaneously after week 12. Those in the placebo group were given 200 mg IV.

Significantly, from the pooled GALAXI 2 and 3 study results, guselkumab also demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission e at Week 48. 3 ...

In a major advance for patients with Crohn’s disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication with a mechanism of action that is new to ...